Kamau Therapeutics key facts
as of Oct 2026- Operator of a clinical-stage, next-generation gene correction company intended to cure serious and life-threatening diseases.
- Kamau Therapeutics is valued at approximately $48.5M as of Oct 2026, set at its seed round, Jun 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $31.8M across 1 recorded rounds; the latest was Seed Round ($5.0M) in May 2025.
- Notable investors include Draper Associates, Modi Ventures, NEVA SGR.
- Kamau Therapeutics has filed 1 Form D with the SEC, most recently Jun 2025 ($5.0M sold to 6 investors).
- Status: Privately Held (backing).
Valued at $48.5M at its seed round, Jun 2025. Nothing has traded since.
- ·Watch Kamau Therapeutics: the Monday email on marks, rounds and moves
Kamau Therapeutics funding rounds
1 roundsWho backs Kamau Therapeutics
3Kamau Therapeutics valuation
Kamau Therapeutics was valued at $48.5 million at its seed round in Jun 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Kamau Therapeutics raised?
Kamau Therapeutics has raised $31.8 million in total; 1 of its rounds is on record. The largest on record was a $5 million seed round in May 2025.
Kamau Therapeutics has filed 1 Form D with the SEC, most recently in Jun 2025 ($5 million sold to 6 investors).
Kamau Therapeutics investors
3 investors are on record for Kamau Therapeutics, including Draper Associates, Modi Ventures and NEVA SGR. By type, the record holds 3 venture capital firms. The seed round in May 2025 drew 6 investors.
About Kamau Therapeutics
Operator of a clinical-stage, next-generation gene correction company intended to cure serious and life-threatening diseases. The company develops a new class of therapies to cure a wide range of serious and life-threatening diseases and uses a gene correction approach, called homology-directed repair (HDR), which overcomes prior limitations in specificity, efficiency, and durability of gene editing to offer broad potential for transforming human health outcomes through the delivery of one-time curative cell therapies, enabling medical practitioners to provide quality treatments to their patients.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2023
- Employees
- 9
- Website
- kamautx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.